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ABSTRACT
The aim of this project was to investigate the in vitro osteogenic potential of human mesenchymal
progenitor cells in novel matrix architectures built by means of a three-dimensional bioresorb-
able synthetic framework in combination with a hydrogel. Human mesenchymal progenitor cells
(hMPCs) were isolated from a human bone marrow aspirate by gradient centrifugation. Before in
vitro engineering of scaffold–hMPC constructs, the adipogenic and osteogenic differentiation po-
tential was demonstrated by staining of neutral lipids and induction of bone-specific proteins, re-
spectively. After expansion in monolayer cultures, the cells were enzymatically detached and then
seeded in combination with a hydrogel into polycaprolactone (PCL) and polycaprolactone–hydroxy-
apatite (PCL–HA) frameworks. This scaffold design concept is characterized by novel matrix ar-
chitecture, good mechanical properties, and slow degradation kinetics of the framework and a bio-
mimetic milieu for cell delivery and proliferation. To induce osteogenic differentiation, the specimens
were cultured in an osteogenic cell culture medium and were maintained in vitro for 6 weeks. Cel-
lular distribution and viability within three-dimensional hMPC bone grafts were documented by
scanning electron microscopy, cell metabolism assays, and confocal laser microscopy. Secretion of
the osteogenic marker molecules type I procollagen and osteocalcin was analyzed by semiquantita-
tive immunocytochemistry assays. Alkaline phosphatase activity was visualized by p-nitrophenyl
phosphate substrate reaction. During osteogenic stimulation, hMPCs proliferated toward and onto
the PCL and PCL–HA scaffold surfaces and metabolic activity increased, reaching a plateau by day
15. The temporal pattern of bone-related marker molecules produced by in vitro tissue-engineered
scaffold–cell constructs revealed that hMPCs differentiated better within the biomimetic matrix ar-
chitecture along the osteogenic lineage.
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INTRODUCTION
BONE MATRIX is produced by cells defined as os-teoblasts, which arise from mesenchymal progenitor
cells in a multistep lineage cascade.1,2 The osteogenic de-
velopmental sequence of mesenchymal progenitors in
vitro is characterized by three defined periods: prolifer-
ation, extracellular matrix maturation, and mineraliza-
tion.3 In vivo, early bone formation is characterized by
the deposition of extracellular matrix (ECM) known as
osteoid, which is subsequently mineralized. The basic
compounds of ECM are collagen type I (95–97%) and
collagen type V (3–5%) and specialized noncollagenous
matrix molecules, such as proteoglycan and glycosami-
noglycan. The major, fibril-forming collagen types I, II,
and III are all synthesized as procollagen molecules
whose N- and C-propeptides removed outside the cell be-
fore or soon after fibril formation. In the formation of
bone collagen type I, a fraction of the N-propeptides are
retained in the bone matrix after it mineralizes in a form
that leaves a single phosphorylated serine residue. Hence,
one of the physical properties that sets demineralized
bone matrix apart from the soft tissue ECM is a failure
to swell in acid and a specific profile for cross-linking
amino acids that leads to superior mechanical properties.
In the early phase of bone healing or remodeling, only a
few areas of mineralization are observed. After prolonged
maturation, minerals—especially hydroxyapatite crys-
tals—are embedded in the ECM. In vivo, fully mineral-
ized ECM is defined as bone matrix. 
At bone defect sites, on a cellular level, the above-de-
scribed biochemical cascades are initiated to form ap-
propriate bone tissue by osteoblast progenitors, which are
recruited from tissues outside the bone (periosteum) and
inside the bone (bone marrow). Repair of bone defects
may be limited by insufficient self-regeneration poten-
tial. However, bone repair may be supported by bio-
compatible osteoinductive or osteoconductive grafts.
Nevertheless, a major challenge for reconstructive sur-
gery is the closure of critical-size defects caused by tu-
mor resection or trauma and to diminish bone loss asso-
ciated with osteoporosis and osteoarthritis. Current,
clinically established therapeutic approaches focus on the
implantation of allografts,4 metal devices,5 or porous
glasses and ceramics6 to assist repair of bone defect sites.
However, all these techniques have disadvantages that
are discussed in detail elsewhere.7 These constraints have
triggered a need for new therapeutic concepts to design
and fabricate better functioning bone grafts. It is within
this context that the field of tissue engineering has
emerged.8 The primary objective of a variety of tissue
engineering strategies is to regenerate structural and func-
tional tissue, using living cells in combination with a 
scaffold. For example, poly(lactic-co-glycolic acid)/poly-
(ethylene glycol) (PLGA/PEG) foams as a three-dimen-
sional model system have been used to study the devel-
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opment of mesenchymal tissues in vitro.9 Porous sponges
fabricated from PLGA and PEG has also been applied as
scaffold material for mammalian bone marrow-derived
cells. In other experiments composites constituted of
porous hydroxyapatite (HA) seeded with mesenchymal
cells showed in vivo osteogenic potential.10 Cross-linked
hyaluran sponges (ACP) as well as benzylated hyaluran
(HYAFF-11) have been used in experiments dealing with
the chondrogenic induction of mesenchymal stem cells
(MSCs) and to treat osteochondral defects.11
The use of synthetic or natural polymer matrices with
low mechanical properties (high porosity) and fast degra-
dation kinetics results in tissue-engineered grafts with
high biological activity, but with poor structural proper-
ties, in particular low strength and stiffness. Such tissue-
engineered grafts can be used in a manner similar to can-
cellous bone chips, for example, in non-load-bearing
applications or in combination with internal or external
fixation devices. In contrast, for the reconstruction of
large and/or load-bearing defects, scaffolds able to with-
stand the forces and stress not only of the wound con-
traction but also of a highly dynamic biomechanical en-
vironment, while the matrix is formed, are required.
Scaffolds made of polycaprolactone (PCL) fabricated by
the rapid prototyping technology of fused deposition
modeling (FDM) exhibit the mechanical properties to be
used in a load-bearing implantation site and a matrix ar-
chitecture that allows for rapid vascularization.12,13 In ad-
dition, use of the highly reproducible and computer-con-
trolled FDM technique for the manufacturing of scaffolds
allows the fabrication of tissue-engineered grafts that
have been designed on the basis of computed tomogra-
phy (CT) scans of individual defect sites.14,15
Currently, one major research thrust in in vitro bone
engineering is focused toward the induction of hard tis-
sue formation by seeding and altering progenitor cells in
such three-dimensional constructs.16 These mesenchymal
progenitor cells reside in various tissues such as muscle
bone marrow and fat.17 Human mesencymal stem cells
(hMSCs) can be isolated from adult bone marrow and
grown in vitro.18,19 Important characteristics of hMSCs
are their ability to proliferate in culture with an attached
fibroblastic morphology, the presence of specific marker
proteins on their surface, and their in vitro multilineage
potential. This potential to differentiate into distinct mes-
enchymal tissues such as bone, cartilage, fat, tendon,
muscle, and stroma19 offers new opportunities for tissue
reconstruction. Although mesenchymal stem cells are
present at a low frequency in bone marrow, their capac-
ity to undergo extensive replication without loss of dif-
ferentiation potential makes them promising candidates
for the regeneration of connective tissue and, especially,
osteogenic tissue repair applications.16,20–22
In the past the osteogenic differentiation of bone mar-
row-derived mesenchymal progenitors isolated from rab-
bits and pigs were studied in vitro and in vivo in designed
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and fabricated by FDM scaffolds.13,14 In the presented in
vitro study we evaluated the osteogenic potential of hu-
man bone marrow-derived mesenchymal progenitor cells
when seeded in combination with a biomimetic hydrogel
into a novel bioresorbable, fully interconnected, three di-
mensional construct of caprolactone or polycaprolac-
tone–hydroxyapatite.
MATERIALS AND METHODS
Scaffold design and fabrication
Polycaprolactone (PCL) scaffolds were fabricated by
fused deposition modeling (FDM) as previously de-
scribed by Hutmacher et al.,14 except that the newest
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FDM techniques (FDM 3000; Stratays, Eden Prairie,
MN) were employed. PCL and PCL–hydroxyapatite
(90:10%) scaffolds, each with a lay-down pattern of
0/60/120° and a porosity of 65% and measuring 103
103 4 mm, were used (Fig. 1). One day before cell seed-
ing, the scaffolds were sterilized in 70% ethanol
overnight. The ethanol was removed by washing three
times in changes of phosphate-buffered saline solution
(PBS). The scaffolds were then transferred for 24 h into
an incubator at 37°C for drying.
Cell isolation and culture
Mesenchymal progenitor cells were isolated via gra-
dient centrifugation, as described previously,23 from il-
iac crest bone marrow aspirates taken from a 2-year-old
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FIG. 1. Representative scanning electron micrographs of a PCL scaffold with a lay-down pattern of 0/60/120° and a porosity
of 65%. The honeycomb pore architecture can be viewed in the 2z direction of the FDM build process (top left, arrows). Com-
puter-controlled alignment of bars and struts in three dimensions results in a fully interconnected channel-like matrix architec-
ture (top right, arrows). High-resolution scanning electron micrograph of a PCL–hydroxyapatite (90:10%) scaffold shows that
the HA is exposed on the surface of the matrix (bottom, arrows).
patient undergoing elective surgery. Cells were seeded at
a density of 1.63 104 cells/cm2. The cells were culti-
vated under standard culture conditions with low-glucose
Dulbecco’s modified Eagle’s medium (DMEM; GIBCO-
BRL, Rockville, MD) supplemented with 10% fetal calf
serum, penicillin (50 U/mL), and streptomycin (50 mg/mL).
Medium was changed after 4 days and then every 3 days
thereafter. When cells had reached 70% confluence they
were detached by the addition of a solution containing
0.25% trypsin–EDTA and replated at a density of 5.53
103 cells/cm2.
Assessment of differentiation potential in 
two-dimensional culture system (control)
After passage 5, the cells were differentiated into os-
teoblasts and adipocytes with the respective induction
medium to prove the multilineage potential of the iso-
lated bone marrow-derived mesenchymal progenitor
cells. Osteogenic and chondrogenic differentiation was
initiated according to the protocol of Owen et al.24 For
adipogenesis, a modified protocol was used to induce dif-
ferentiation of progenitor cells by the use of 0.2 mM in-
domethacin.25 Chondrogenic lineage formation was ana-
lyzed by histology. Osteogenic differentiation was
demonstrated by alkaline phosphatase staining with fast
red and immunoassaying with a monoclonal mouse anti-
human antibody (100 mg/mL; 1:50 dilution) against os-
teocalcin (Biodesign International, Kennebunk, ME). For
visualization the EnVision system (horseradish peroxi-
dase [HRP], diaminobenzidine [DAB]; Dako, Carpinte-
ria, CA) was used according to the manufacturer’s pro-
tocol. Adipogenic differentiation was demonstrated by oil
red O staining.
Assessment of differentiation potential in 
three-dimensional culture system
Noninduced progenitor cells of passage 5 were de-
tached by trypsin–EDTA treatment, washed with PBS,
and seeded into polycaprolactone (PCL) and PCL–hy-
droxyapatite (90:10%) scaffolds. The cells were resus-
pended in fibrinogen at a ratio of 2:1, reaching a con-
centration of 3 3 106 cells/mL. Both PCL and PLC–HA
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frameworks were loaded with 40 mL of fibrinogen–cell
suspension, resulting in a seeding density of 3 3 106 mes-
enchymal progenitor cells (MPCs). Twenty milliliters of
thrombin (500 U) was used to polymerize the cell–
fibrinogen matrix inside the completely interconnected
and honeycomb pore architecture. The specimens were
cultured under static conditions in standard cell culture
medium for 2 days. Thereafter, medium was changed and
the specimens were cultured in osteogenic medium I for
7 days and for 5 weeks in osteogenic medium II as de-
scribed.24 During the culture period, supernatants were
collected after specific time points as indicated before
medium exchange and stored at 280°C.The cell culture
media protocol for osteogenic differentiation in mono-
layers was transferred directly to three-dimensional cul-
tivation of progenitor cells within PCL and PCL–HA
scaffolds. However, for three-dimensional reassembly of
mesenchymal progenitors and optimal seeding efficiency
and efficacy, cells were embedded in a biomimetic fibrin
matrix to temporarily immobilize them and to obtain a
three-dimensional homogeneous distribution of cells
within the large size and fully interconnected pore ar-
chitecture (Figs. 1–3).
Histology
Five-micron-thick sections from the 6-week culture
group of scaffold–cell constructs were cut with a cryo-
microtome (RM 2165; Leica, Bensheim, Germany) and
mounted on poly-L-lysine (Sigma, St. Louis, MO)-coated
slides. Slides were stained with von Kossa silver nitrate.
Metabolic assay
Both scaffold–cell construct groups were assayed for
procollagen type I, osteocalcin, and alkaline phosphatase
as osteogenic markers, The C-terminal propeptide of col-
lagen type I was determined in the supernatants (n 5 2)
of the seeded specimen, using a human-specific enzyme-
linked immunosorbent assay (ELISA) (Prolagen-C; Me-
tra Biosystems, Mountain View, CA) according to the
manufacturer’s protocol. The concentration of bone GIa
protein (BGP-osteocalcin) in the supernatants (n 5 2) of
cell-bearing matrices and two-dimensional cell cultures
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FIG. 2. (A) Morphological appearance of isolated human progenitor cells after 9 days in monolayer culture. (B) Phase-contrast
microscopy of a confluent monolayer of hMPCs induced down the chondrogenic pathway. (C) Immunocytochemistry with an
osteocalcin antibody after osteogenic differentiation in monolayer culture. (D) Adipogenic differentiation detected via oil red O
staining of lipid droplets and lipid vacuoles. Original magnification: (A and B) 340; (C and D) 3100.
FIG. 3. (A–D) Representative phase-contrast microscopy images 2 days after seeding undifferentiated human progenitor cells
into PCL scaffolds (A and B) and PCL–HA frameworks (C and D). Independent of the framework matrix, the cells 
initially remain round (arrows), when fibrin as a temporary biomimectic cell carrier is used. Seven days postseeding undifferen-
tiated human progenitor cells have established a fibroblast-like morphology (arrows) and migrate and proliferate in three di-
mensions within the hydrogel (B and D).
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was determined by an osteocalcin ELISA (h-Ost EAIA
kit; Biosource, Nivelles, Belgium) according to the man-
ufacturer’s protocol. Extinction was measured at 405 nm,
using an Antos Hill microplate reader. The amount of al-
kaline phosphatase (ALP) (n 5 1) was quantified by
measuring the conversion to p-nitrophenol from p-nitro-
phenyl phosphate according to the manufacturer’s proto-
col (Sigma). Cell metabolism and viability were analyzed
via MTS test according to the supplier’s protocol
(Promega, Madison, WI).
Phase-contrast, scanning electron, and confocal
laser microscopy
Adhesion, proliferation, and distribution of the cells
were studied by phase-contrast light microscopy (IX70;
Olympus, Tokyo, Japan). The establishment of the cell
phenotype, intercellular connections, and extracellular
matrix production were examined every second day. Rou-
tine qualitative analysis of cell attachment and prolifera-
tion in the scaffold–cell constructs was performed by
phalloidin–propidium iodide (PI) staining whereas cell
viability was documented via fluorescein diacetate–pro-
pidium iodide (FDA–PI) staining as described previ-
ously,26 using an Olympus IX70-HLSH100 Fluoview
confocal laser microscope. A Leica TCS SP2 (Leica Mi-
crosystems, Singapore) in combination with a custom-
made Leica long lens objective (310) was used to view
the proliferation and ECM formation deep inside the scaf-
fold–cell constructs. Depth projection images were con-
structed from up to 50 horizontal image sections (20 mm
each) through the stained scaffold–cell constructs.
For scanning electron microscopy (SEM), specimens
were fixed with 2.5% glutaraldehyde for 4 h at 4°C. Sam-
ples were dehydrated in a graded ethanol series of 30, 50,
90, and 100%, dried, gold sputtered, and examined by
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SEM (JSM-5800LV; UEOL, Tokyo, Japan) at 15 kV, us-
ing the low-vacuum mode.
RESULTS
Isolation and differentiation in 
two-dimensional cultures
Human mesenchymal progenitors were successfully
isolated from bone marrow aspirates, via gradient cen-
trifugation, expanded in monolayer culture, and evalu-
ated for osteogenic, chondrogenic and adipogenic differ-
entiation potential (Fig. 2). The progenitor cells grew in
distinct colonies and demonstrated a fibroblastic mor-
phology (Fig. 2A) as first described by the groups of 
Caplan16 and Haynesworth.19 In addition, a small num-
ber of cells described in the literature as flat cells were
also observed.27,28 The fibroblastic morphology re-
mained stable during prolonged culture and subculture in
monolayers (Fig. 1, left). With passaging, routine phase-
contrast microscopy did show that flat cells were over-
grown by the fibroblast-like cells (micrographs not
shown).
Following in vitro induction mesenchymal progenitors
continued to proliferate and readily formed multilayers
showing differentiation along all three lineages. By day
7, the chondrogenic (Fig. 2B) and osteogenic (Fig. 2C)
differentiation potential was confirmed via cell mor-
phology as well as visualization of alkaline phosphatase
(ALP) activity (data not shown) and via immunostaining
of the bone-specific matrix protein osteocalcin. After in
vitro induction of adipogenic differentiation, staining
with oil red O revealed cells filled with neutral lipid
droplets, which substantiated the potential of the human
bone marrow-derived progenitors to differentiate along
the adipogenic lineage (Fig. 2D).
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FIG. 4. (A and D) Representative scanning electron microscopy images of human progenitor cells adhering at the bars of PCL
(A) and PCL–HA frameworks (B) and building cell bridges within the interconnected pore architecture. Cells use the biomimetic
hydrogel as a three-dimensional template to migrate and proliferate inside the pore architecture to bridge the bars and struts of
the PCL-based framework. The viability of the cells in the scaffold was detected via confocal laser microscopy (C and D) by us-
ing fluorescence markers that allow life/death stain (PI/FDA): dead cells were stained red whereas viable cells were stained green.
The qualitative image analysis revealed that a large number of cells stayed viable throughout the entire culture period. Original
magnification: (A) 31609; (B) 3804; (C) 3100; (D) 3100.
FIG. 5. (A and B) Special confocal laser microscopy was performed to view proliferation and ECM formation deep inside scaf-
fold–cell constructs. A custom-made Leica long lens objective (310) allowed generation of depth projection images of up to 1
mm. Three-dimensional images were constructed from up to 50 horizontal image sections (20 mm) taken within the scaffold–cell
constructs. In this phalloidin–propidium iodide-stained specimen, adhesion and proliferation of the MPCs on the PCL surface
(left) and cell-to-cell contact are shown by studying the actin fiber (green) and cell nucleus (red) arrangement. Intracellular bun-
dles of F-actin filament (stress fibers) indicate the formation of focal adhesions. The cells are forming focal contact patches on
the bars and struts of the framework whereas prominent intracellular F-actin filaments can be detected when cells are bridging
throughout pores (left and right, arrows). Comparing these micrographs obtained by phalloidin–PI staining with the SEM images
in Fig. 4A and B further reveals the proliferation and colonization pattern of the hMPCs. Starting at week 2, the cells appear to
span three-dimensionally across the pore structure by cell-to-cell and cell-to-ECM contact, preferably by way of the interjunc-
tions of the columns and rods of the honeycomb scaffold architecture (right, arrows).
OSTEOGENIC INDUCTION OF hMPCs 695
FIG. 4.
FIG. 5.
Cell growth and differentiation in 
scaffold–cell constructs
During the first 4 days of culture, the cells remained
round shaped within the hydrogel and revealed a homo-
geneous distribution within the PCL (Fig. 3A) and
PCL–HA (Fig. 3C) scaffolds. Starting on day 5, the cells
began to stretch and proliferated within the biomimetic
hydrogel and showed a fibroblast-like phenotype within
both matrix materials (Fig. 3B and D). Scanning electron
(Fig. 4A and B) and confocal laser (Fig. 4C and D) mi-
croscopy revealed the adherence of mesenchymal pro-
genitors onto the PCL and PCL–HA fibers and, after 2
weeks in culture, bridging the pores of both scaffolds via
the production of ECM. Henceforth, phase–contrast mi-
croscopy and SEM showed that after 3 weeks the entire
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architecture of both scaffold groups was filled with cells
and ECM. This was in accordance with confocal laser
microscopy (CLM) images taken deep inside the FDM-
fabricated frameworks 3 weeks postseeding (Fig. 5).
Qualitative examination via routine CLM of cells did re-
veal that a large number of cells stayed active for the en-
tire culture period, which was in conformity with the
semiquantitative immunoassays (Fig. 6).
On the basis of the imaging data a significant differ-
ence between PCL and PCL–HA with respect to the pro-
liferation pattern of the induced hMPCs could not be de-
tected. The MTS test revealed an almost linear increase
in cell metabolism for 15 days until a constant metabolic
level was reached after 20 days of culture (Fig. 6A). This
was in accordance with image analysis, which revealed
that after prolonged cultivation of scaffold–cell con-
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FIG. 6. (A–D) Cell metabolism in the scaffold–cell constructs of both groups was detected via MTS test during the entire cul-
ture period (A). Also assessed was procollagen I (B), alkaline phosphatase (D), and osteocalcin (D) secretion by human progen-
itor cells in a three-dimensional environment during 6 weeks of culture. The up-and-down regulation of ALP and osteocalcin
(OC) activity for both construct groups is related to the fact that the MPC population is inhomogeneous, that is, they are in dif-
ferent stages of their cell cycle. ALP is a marker for actively proliferating cells and it can be argued that most of the MPCs stayed
in the proliferative phase until the entire pore architecture of the framework was filled with cells and ECM (week 3 to 4). In con-
trast, OC is known to be secreted by differentiated cells. It could be detected at the late stage of the culturing period; when the
entire construct was filled with cells and mineralized matrix (see also von Kossa staining) OC showed a strong linear increase
because most of the induced MPCs were driven down the osteogenic pathway.
structs, by day 28, FDA–PI staining still showed vital fi-
brocytic cells inside the honeycomb scaffold architecture
(data not shown).
During osteogenic differentiation of human mes-
enchymal progenitors in three-dimensional PCL and
PCL–HA scaffolds, viability, physiological activity, as
well as osteogenic marker proteins were documented by
MTS (Fig. 6A) and also by quantitative ELISAs. The os-
teogenic marker proteins collagen type I, alkaline phos-
phatase (ALP), and osteocalcin were also assessed (Fig.
6B–D). The qualitative determination of cell viability and
physiological activity via MTS assay revealed a steadily
increasing activity of mesenchymal progenitors within
the first days of three-dimensional culture in PCL scaf-
folds. By day 15, the activity reached a plateau and re-
mained constant during further cultivation. Initially cells
in the PCL–HA scaffolds showed less metabolic activity
reaching the same plateau as the PCL specimen by day
28 (Fig. 6A).
Quantitative analysis of osteogenic marker proteins
revealed a decreased secretion of procollagen type I for
mesenchymal progenitors seeded onto PCL scaffolds
during the culture in osteogenic medium I (OM-I) up to
day 7. After stimulation with osteogenic medium II
(OM-II) the amount of procollagen type I increased
slightly, but decreased again to reach a relatively stabi-
lized secretion level between 48 and 58 ng/mL. The
course of PCL–HA is similar to PCL but reached a se-
cretion level between 42 and 40 ng/mL (Fig. 6B). The
amount of secreted ALP, instead, showed a more dy-
namic course during the culture period (Fig. 6C). Di-
rectly after stimulation of mesenchymal progenitors
with OM-I, the amount of secreted ALP increased and
displayed a maximum ALP level of 47 nmol/mL for
PCL and 20 nmol/mL for PCL–HA on day 4. Up to day
7, the amount of ALP decreased for both materials and
was induced again by stimulation with OM-II, resulting
in a maximum secretion of 58 nmol/mL. By day 16, the
cultivation of progenitors within the PCL scaffolds with
OM-II revealed a decreasing secretion of ALP, which
reduced the amount of ALP to 12 nmol/mL on day 45.
PCL–HA showed also a decreasing secretion of ALP to
a minimum of 20 ng/mL on day 45.
Compared with ALP, secretion of osteocalcin demon-
strated an almost inverse course (Fig. 6D). During the
early periods of osteogenic stimulation up to day 14, the
amount of osteocalcin decreased when ALP was induced
by OM-I or OM-II and vice versa. Remarkably, on day
28, the amount of osteocalcin was low (12 ng/mL, PCL;
31 ng/mL, PCL–HA), but increased again during further
culture in osteogenic medium, leading to osteocalcin se-
cretion at 38 ng/mL on day 45 in PCL scaffolds and at
26 ng/mL in PCL–HA scaffolds. These results were con-
firmed by von Kossa staining (Fig. 7), which showed
mineralized areas on the scaffold bars and struts as well
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as in the honeycomb pore architecture after 6 weeks of
culturing in an osteogenic medium.
DISCUSSION
Adult stem cells are sparsely distributed in the body
and their main functions are 2-fold: first, to produce iden-
tical copies of themselves for long periods of time, which
is also referred to in the stem cell literature as the ca-
pacity for long-term self-renewal; second, to engender
transitional cell types before they reach the end of the
differentiation cascade. The intermediate cell is defined
as a progenitor or precursor cell, a cell that is regarded
as committed to differentiate along a particular cellular
pathway.16,17
In the present study, we have reported the in vitro os-
teogenic differentiation potential of human bone marrow-
derived mesenchymal progenitors in novel matrix archi-
tectures that were built by using a three-dimensional
bioresorbable synthetic framework in combination with
a hydrogel. The PCL and PCL–HA scaffolds have hon-
eycomb matrix architecture and mechanical properties
suitable for maintenance of the structural integrity of tis-
sue-engineered bone grafts in load-bearing applications.
The fibrin glue-based hydrogel presents to the cells a bio-
mimetic environment that supports cell attachment, mi-
gration, and production of ECM in three dimensions.
Bone marrow has been considered a source of pro-
genitor cells for mesenchymal and hematopoetic tissues.
Previous results indicated that mesenchymal progenitor
cells from human bone marrow have the potential to dif-
ferentiate into distinct mesenchymal lineage cells in-
cluding osteoblasts,29 chondrocytes,30 adipocytes,31 teno-
cytes,32 and marrow stromal cells.21 The multipotent
nature of bone marrow-derived cells might be based on
particular mono- or bipotential precursor cells, which are
able to differentiate into distinct mesenchymal cell types,
or on multipotent stem cells differentiating into various
mesenchymal tissues.16,18 We demonstrated that for this
experiment isolated mesenchymal progenitors derived
from juvenile bone marrow have the potential to undergo
multiple differentiation pathways. Although it has been
suggested that osteoblasts and adipocytes share common
precursors within the adult stromal system,31 human bone
marrow-derived precursors showed no obvious differen-
tiation into adipocytic cells, when stimulated with os-
teogenic medium supplemented with dexamethasone
(Dex) in monolayers. In other studies, depending on the
presence of Dex in primary or secondary cultures of mar-
row stromal cells, an inverse relationship between the dif-
ferentiation of adipocytic and osteogenic cells in marrow
stromal cells has been reported.33
A great number of processing techniques have been
developed to design and fabricate three-dimensional scaf-
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folds for bone tissue engineering.33a A wide range of scaf-
fold characteristics, such as porosity and pore size, has
been reported using such fabrication techniques.
However, no single technique has allowed researchers
to design and fabricate scaffolds with a completely in-
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terconnected pore network, highly regular and repro-
ducible scaffold morphology, microstructure that varies
across the scaffold matrix, and that is solvent-free, using
a computer-controlled process. These are essential scaf-
fold features to facilitate cell proliferation and differen-
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FIG. 7. Representative histological sections of cultured scaffold–cell constructs (top, PCL; bottom, PCL–HA). Osteogenic in-
duction and long-term culturing (6 weeks) resulted in mineralized ECM formation. Both groups showed, on von Kossa silver ni-
trate staining, dark brown-black areas (arrows) of calcium phosphate deposits on the bars and struts as well as in the pore ar-
chitecture. Scale bars: top and bottom, 50 mm.
tiation, extracellular matrix synthesis, and flow transport
of nutrients and wastes. Equally important from a clini-
cal point of view is to apply a design and material strat-
egy in which the scaffold should protect proliferating
cells and their extracellular matrix, inside the pore net-
work, from being mechanically overloaded for a suffi-
cient period of time and maintain the shape until a ma-
ture tissue is formed inside the entire porous scaffold
architecture.15
Rapid prototyping technologies have emerged that can
be used to manufacture scaffolds with more suitable
structural and mechanical properties for bone and carti-
lage regeneration. Hutmacher and co-workers12–14 de-
signed and fabricated novel polycaprolactone (PCL) scaf-
folds by fused deposition modeling, which offers the
possibility to design and fabricate highly reproducible
bioresorbable three-dimensional scaffolds with a fully in-
terconnected pore network and outstanding physical
properties. Arranged in a regular manner, interconnected
three-dimensional channels are produced and the design
of a pore morphology, which varies across the scaffold
structure, is allowed. Scaffolds with a porosity of 60 to
65% have mechanical properties in the range of cancel-
lous bone and have been studied in bone tissue engi-
neering by using differentiated osteoblast-like cells.
A great number of the currently applied scaffold de-
signs (foams, textiles, etc.) use fast-degrading polymers
combined with a high porosity matrix (.90%). These
types of matrices do not possess the structural stability
to be applied in the reconstruction of bone defects that
are medium to large and/or load bearing.15 Therefore, we
present in this article a scaffold–cell construct design that
consists of a mechanically stable structural framework
fabricated from a slow-degrading polymer. Beside me-
chanical stability, another important property of this con-
struct is to support three-dimensional tissue development
and progenitor cell differentiation within the honeycomb
matrix architecture by using a biomimetic hydrogel as
temporary cell carrier.
Surface engineering may potentially be used to create
matrices that elicit controlled cellular adhesion and main-
tain differentiated phenotypic expression. Such modifi-
cations generally involve enriching surfaces with extra-
cellular matrix (ECM) components (such as the adhesive
protein fibronectin, FN), or their functional domains.33b
However, a technically much easier and more physio-
logical approach is to use a biomimetic cell carrier, which
contains ECM factors, to deliver the cells into a scaffold
made of a synthetic polymer. On the basis of this strat-
egy the advantages of synthetic and natural polymers can
be straightforwardly combined.
Healing of most mesenchymal tissue in the body de-
pends on the blood clot and consequently fibrin forma-
tion (fibrinogen is converted to fibrin in the formation of
a blood clot, via the enzymatic action of thrombin), as a
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matrix for cell migration and a subsequent cascade of bi-
ological activities that lead to the eventual formation of
reparative tissue in the defect.40 As reported by a num-
ber of tissue-engineering groups and confirmed once
again by the results of this study, fibrin provides an ex-
cellent biomimetic environment for delivering and cul-
turing mesenchymal cells in a synthetic polymer-based
three-dimensional scaffold.
It is known that if cells are directed into the osteogenic
lineage, ALP is an early differentiation marker but the
cells maintain a strong proliferative capacity. Hence, an
increased production of ALP was observed until it peaked
on day 20 for PCL and on day 25 for PCL–HA. SEM,
phase-contrast light microscopy, and confocal laser mi-
croscopy confirmed that at this period of culturing the
entire scaffold architecture was filled with cells and
ECM.
Several authors have studied the synthesis of ALP and
osteocalcin (OC) of osteoblast-like cells in vitro.24,41–43
ALP is an early marker in osteogenesis whereas OC is
known as a late marker. In this study, a strong cyclic ex-
pression of osteocalcin was observed for the first 3 weeks.
This is most likely related to the inhomogeneous cell pop-
ulation, which is common for primary cells from bone
marrow aspirates. However, it was during the late stage
of the culturing period, when the entire scaffold archi-
tecture was filled with cells and mineralized matrix (see
von Kossa staining), that osteocalcin showed a strong lin-
ear increase.
Fibrillar type I collagen of the ECM of bone differs in
physical and chemical properties from polymers of the
same molecular type of collagen in nonmineralized tis-
sues. The unique physical properties of bone collagen
have not been fully explained at the molecular level, al-
though the distinctive cross-linking chemistry is one sus-
pected factor. Carboxy-terminal propeptide of type I col-
lagen (PICP) and bone Gla-protein-osteocalcin (BGP) are
among the most important components of the organic
bone matrix and play a key role in bone formation.44–45
Propeptides of collagen types I, II, III are present in serum
and as by-products of metabolic activity. Hence, clinical
immunoassays for measuring propeptides in the blood
have been developed and routinely applied. Although
propeptide I evaluated in serum correlates with serum os-
teocalcin and alkaline phospatase activity, it is generally
less sensitive than these other two bone formation mark-
ers.46
To our knowledge this is the first time that a procol-
lagen type I ELISA kit was used to study its expression
in in vitro bone engineering. PICP expression showed a
cyclic up- and downregulation for both scaffold types for
the first 15 days of culture. One week after the second
time of induction PCIP showed a slow linear increase for
the rest of the culture period. These semiquantitative data
correlate with the microscopy data, which showed that
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both PCL- and PCL–HA-based constructs were com-
pletely filled with cells and ECM at the end of the cul-
turing period.
At present, aliphatic polyesters, such as poly(lactic
acid) (PLA), poly(glycolic acid) (PGA) and PCL, are by
far the most applied synthetic polymer materials in the
fabrication of scaffolds. In general, polymers of the
aliphatic polyester group undergo bulk degradation and
their molecular weight, in addition to their mechanical
properties, begin to decrease within weeks [PGA, poly(D-
lactic acid) (PDLA), etc.] or within a few months to years
[poly(L-lactic acid) (PLLA), PCL, etc.] of placement 
in an aqueous medium. However, the mass loss does 
not start until the molecular chains are reduced to a size
that allows them to freely diffuse out of the polymer ma-
trix. This phenomenon, described and analyzed in detail
by a number of research groups,47–50 results in acceler-
ated degradation and resorption kinetics until the physi-
cal integrity of polymer matrix is compromised. The mass
loss is accompanied by a release gradient of acidic by-
products.
Potential problems of biocompatibility in tissue-engi-
neering bone, using synthetic polymer scaffolds, may
also be related to biodegradability and bioresorbability.
Rotter et al.51 report that a high amount of resorption by-
products of fast-degrading textile-based scaffold made of
PGA–PLA (10/90%) can lead to cell death. The incor-
poration of tricalcium phosphate (TCP),52 hydroxyapatite
(HA),53 and basic salts54 into a polymer matrix system
produces a hybrid or composite material. These inorganic
fillers allow tailoring of the degradation and resorption
kinetics of the polymer matrix. A composite material
would also improve biocompatibility and hard tissue in-
tegration in that ceramic particles, which are embedded
into the synthetic polymer matrix, allow for increased ini-
tial flash spread of serum proteins compared with the more
hydrophobic polymer surface. In addition, the basic re-
sorption products of HA or TCP would buffer the acidic
resorption by-products of the aliphatic polyester and may
thereby help to avoid the formation of an unfavorable en-
vironment for the cells caused by decreased pH.
The data generated in this study did not show a statis-
tically significant difference when human mesenchymal
progenitor cells in combination with fibrin as cell carrier
were cultured over period of 3 weeks in honeycomb-like
scaffold architectures made of PCL or PCL–HA. As a
next step toward a clinical application, the cell response
as well as the properties of the tissue-engineered bone in-
side the novel PCL and PCL–HA scaffold must be stud-
ied in an accelerated degradation model or in real-time
experiments spanning a period of up to 2 years. Such
studies are currently being performed in the Tissue En-




The concept of a mechanically stable framework made
of a slow degrading polymer and hydrogel with bio-
mimetic properties has allowed the design of a new gen-
eration of scaffold/cell/tissue constructs. Fibrin gel might
be the ideal temporary biomimetic cell carrier in such
composite constructs because it is a clinically approved
material, has been used extensively in the clinical setting
as a tissue adhesive, can also be obtained from a patient’s
own blood, and stimulates in vivo vascularization. This
in vitro study demonstrated that human bone marrow de-
rived osteoprogenitor cells delivered in a fibrin matrix
can be induced to the osteogenic lineage in novel PCL
and PCL–HA scaffold architectures.
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